Skip to main content
Clinical Trials/NCT01764269
NCT01764269CompletedNot Applicable

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

Columbia University2 sites in 1 country656 target enrollmentStarted: January 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
656
Locations
2
Primary Endpoint
fever

Study Overview

Brief Summary

In this study, the investigators will prospectively assess fever rates in 24-59 month old patients during days 0-10 after administration of inactivated influenza vaccine (IIV) or live attenuated influenza vaccine (LAIV). Children in one of three study sites who receive these vaccines as part of their routine care can enroll in this study if their parent has the ability to receive and send text messages. Children enrolled in this study will be observed for an eleven day period starting on the day of vaccine administration via a series text messages to their parents.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
24 Months to 59 Months (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •are 24 through 59 months of age,
  • •have a visit at a study site anytime during the study period,
  • •receive first dose LAIV or IIV in the season,
  • •the parent has a cell phone with text messaging capabilities, and
  • •the parent speaks English or Spanish.

Exclusion Criteria

  • •any chronic medical condition in the child that precludes receipt of LAIV (except for history of asthma or a wheezing episode within the past 12 months noted in the medical record),
  • •currently on oral or other systemic steroids or used in the past month,
  • •currently on inhaled steroids or used in the past 2 weeks,
  • •presence of fever >=100.4 at time of vaccination,
  • •administration of any antipyretic in the 6-hour period prior to vaccination,
  • •stated intent, at time of vaccination, to use prophylactic antipyretics before the development of a fever,
  • •parent only speaks a language other than English or Spanish,
  • •parent's inability to read text messages,
  • •child receiving the second dose of influenza vaccine in the current season.

Arms & Interventions

inactivated influenza vaccine (IIV)

Other

Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)

Intervention: text message surveillance for fever (Other)

Live attenuated influenza vaccine (LAIV)

Other

Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)

Intervention: text message surveillance for fever (Other)

Outcomes

Primary Outcomes

fever

Time Frame: 11 days

day of vaccination plus 10 more days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Melissa Stockwell, MD, MPH

Assistant Professor of Pediatrics and Population and Family Health

Columbia University

Study Sites (2)

Loading locations...

Similar Trials